If youre living with bronchiectasis, youre likely familiar with the exhausting cycle of thick mucus, chronic coughing, and fear of the next flare-up. For years, treatment has focused on managing ...

If you’re living with bronchiectasis, you’re likely familiar with the exhausting cycle of thick mucus, chronic coughing, and fear of the next flare-up. For years, treatment has focused on managing ...

MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for brensocatib, branded as ...

DPP‑1 inhibitors and long‑term macrolides appeared to effectively reduce the frequency of exacerbations in patients with non-cystic fibrosis bronchiectasis compared with placebo, with macrolides ...

It started out as a typical hot yoga class for Lavonda. The North Carolina resident was used to strenuous workouts, but on this day in 2008 she felt faint as she went through the sequence of poses.

Bronchiectasis hospitalizations have higher mortality and costs than COPD and asthma, with a median stay of 5 days and costs of $50,393. During the COVID-19 pandemic, bronchiectasis hospitalizations ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Bronchiectasis is a long-term lung condition where the airways stay widened and inflamed. These airway changes make it harder to breathe and clear mucus. People with bronchiectasis live with a ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. The FDA has signed off on ...